Company Filing History:
Years Active: 2013-2017
Title: Philippe Delay-Goyet: Innovator in Neuropharmacology
Introduction
Philippe Delay-Goyet is a notable inventor based in Paris, France. He has made significant contributions to the field of neuropharmacology, particularly in the treatment of neurodegenerative diseases. With a total of 3 patents, his work focuses on innovative therapeutic approaches.
Latest Patents
One of Delay-Goyet's latest patents is an H3 receptor antagonist for use in the treatment of Alzheimer's disease. This patent discloses methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in disease-modifying therapy for Alzheimer's disease and related tauopathies. Another significant invention involves the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament aimed at treating cerebral traumas.
Career Highlights
Throughout his career, Philippe Delay-Goyet has worked with prominent companies such as Sanofi and Sanofi-Aventis. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical industry.
Collaborations
Delay-Goyet has collaborated with notable colleagues, including Badia Ferzaz and Jocelyne Lolivier. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Philippe Delay-Goyet is a distinguished inventor whose work in neuropharmacology has the potential to impact the treatment of Alzheimer's disease and other neurodegenerative conditions. His innovative patents and collaborations highlight his commitment to advancing medical science.